Systems biology embedded target validation: improving efficacy in drug discovery
暂无分享,去创建一个
Walter Kolch | William Fitzmaurice | Drieke Vandamme | Boris N Kholodenko | Benedikt A Minke | B. Kholodenko | W. Kolch | D. Vandamme | W. Fitzmaurice | B. Minke
[1] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[2] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[3] P. Sorger,et al. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.
[4] Charles Auffray,et al. Application of ’omics technologies to biomarker discovery in inflammatory lung diseases , 2013, European Respiratory Journal.
[5] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[6] Khusru Asadullah,et al. What makes a good drug target? , 2011, Drug discovery today.
[7] Daniel M. Johnstone,et al. Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. , 2012, Pharmacology & therapeutics.
[8] M. Tewari,et al. The Limits of Reductionism in Medicine: Could Systems Biology Offer an Alternative? , 2006, PLoS medicine.
[9] Josep Roca,et al. A Systems Biology Approach Identifies Molecular Networks Defining Skeletal Muscle Abnormalities in Chronic Obstructive Pulmonary Disease , 2011, PLoS Comput. Biol..
[10] K. Shokat,et al. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. , 2011, Annual review of biochemistry.
[11] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[12] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[13] Peter Høngaard Andersen,et al. Priorities for improving drug research, development and regulation , 2013, Nature Reviews Drug Discovery.
[14] C. Mehta,et al. The future of drug development: advancing clinical trial design , 2009, Nature Reviews Drug Discovery.
[15] Joanna M. Sasin,et al. Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.
[16] Albert-László Barabási,et al. Network-based Analysis of Genome Wide Association Data Provides Novel Candidate Genes for Lipid and Lipoprotein Traits* , 2013, Molecular & Cellular Proteomics.
[17] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[18] Igor Goryanin,et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.
[19] F. Azuaje,et al. Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs , 2011, Scientific reports.
[20] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[21] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[22] M. Rask-Andersen,et al. Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.
[23] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[24] Joseph Loscalzo,et al. Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[25] B. Ladizinski,et al. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. , 2010, Journal of drugs in dermatology : JDD.
[26] J. DiMasi,et al. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.
[27] S. Kingsmore,et al. Genome-wide association studies: progress and potential for drug discovery and development , 2008, Nature Reviews Drug Discovery.
[28] International consortium completes human genome project. , 2003, Pharmacogenomics.
[29] S. Iacobelli,et al. Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin–5-Fluorouracil–Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963) , 2011, Chronobiology international.
[30] Melvin E Andersen,et al. Dose-response modeling in reproductive toxicology in the systems biology era. , 2005, Reproductive toxicology.
[31] M. Mann,et al. Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics , 2009, Molecular & Cellular Proteomics.
[32] S. Safe,et al. Aspirin Inhibits Colon Cancer Cell and Tumor Growth and Downregulates Specificity Protein (Sp) Transcription Factors , 2012, PloS one.
[33] Sridhar Ramaswamy,et al. Rational design of cancer-drug combinations. , 2007, The New England journal of medicine.
[34] N. Trayanova,et al. A Computational Model to Predict the Effects of Class I Anti-Arrhythmic Drugs on Ventricular Rhythms , 2011, Science Translational Medicine.
[35] Gary R. Mirams,et al. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.
[36] Jan Lankelma,et al. Principles behind the multifarious control of signal transduction , 2004, The FEBS journal.
[37] Susumu Goto,et al. Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocorticoid actions in asthmatics , 2012, BMC Medical Genomics.
[38] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[39] Boris N. Kholodenko,et al. Signalling ballet in space and time , 2010, Nature Reviews Molecular Cell Biology.
[40] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[41] E. Hafen,et al. A Novel, Evolutionarily Conserved Protein Phosphatase Complex Involved in Cisplatin Sensitivity*S , 2005, Molecular & Cellular Proteomics.
[42] P. Hajduk,et al. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.
[43] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[44] David R. Croucher,et al. Signalling by protein phosphatases and drug development: a systems‐centred view , 2012, The FEBS journal.
[45] D. Kell,et al. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it , 2013, The FEBS journal.
[46] J. Shryock,et al. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine , 2006, Heart.
[47] T. Ideker,et al. Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.
[48] Xiaobo Zhou,et al. Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma , 2011, PloS one.
[49] P J Noble,et al. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium–calcium overload , 2006, Heart.
[50] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[51] Gerhard Dürnberger,et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.
[52] A. Barr. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. , 2010, Future medicinal chemistry.
[53] F. Lévi,et al. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. , 2013, Handbook of experimental pharmacology.
[54] D. J. Ashley,et al. The two "hit" and multiple "hit" theories of carcinogenesis. , 1969, British Journal of Cancer.
[55] H. Handa,et al. Teratogenic effects of thalidomide: molecular mechanisms , 2011, Cellular and Molecular Life Sciences.
[56] Muffy Calder,et al. The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier , 2010, Science Signaling.
[57] T. Reiss. Drug discovery of the future: the implications of the human genome project. , 2001, Trends in biotechnology.
[58] B. Garvik,et al. Principles for the Buffering of Genetic Variation , 2001, Science.
[59] Albert Goldbeter,et al. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[60] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[61] Annabelle Ballesta,et al. A Combined Experimental and Mathematical Approach for Molecular-based Optimization of Irinotecan Circadian Delivery , 2011, PLoS Comput. Biol..
[62] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[63] Sumit K Chanda,et al. Fulfilling the promise: drug discovery in the post-genomic era. , 2003, Drug discovery today.
[64] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[65] Martin Vingron,et al. A systems biological approach suggests that transcriptional feedback regulation by dual‐specificity phosphatase 6 shapes extracellular signal‐related kinase activity in RAS‐transformed fibroblasts , 2009, The FEBS journal.
[66] Vikram Sinha,et al. Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.
[67] B. Kholodenko,et al. Systems medicine: helping us understand the complexity of disease. , 2013, QJM : monthly journal of the Association of Physicians.
[68] R. Hällgren,et al. The timing of glucocorticoid administration in rheumatoid arthritis , 1997, Annals of the rheumatic diseases.
[69] Jorge Cortes,et al. Systems approaches and algorithms for discovery of combinatorial therapies. , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.
[70] E. Petricoin,et al. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks , 2007, Nature Reviews Drug Discovery.